For decades, neutrophils have been seen as simple, short-lived immune cells whose primary role was to rush to sites of infection, kill pathogens, and die. This narrow view is changing rapidly. We now understand that neutrophils are far from uniform; they are remarkably versatile and exist as diverse subsets, each with distinct transcriptional profiles, functional capabilities and roles in health and disease. Some subsets drive inflammation and tissue damage, others promote resolution and repair and still others can modulate the immune response in cancer and chronic disease.

​

We believe that embracing this complexity is essential for the next generation of immunology. By dissecting the unique properties of neutrophil subsets, how they arise, how they function and how they interact with other immune and non-immune cells, we can begin to harness their power with unprecedented precision.

​

This vision inspired us to develop a first-of-its-kind platform for neutrophil-specific drug delivery. This technology enables us to modulate neutrophil function in vivo without affecting other immune cell populations, opening the door to cell-specific immunotherapies that avoid the systemic side effects of traditional treatments. The platform has already moved from concept to real-world application, forming the scientific foundation of Immunyx Pharma, a biotechnology startup dedicated to bringing neutrophil-targeted therapies to patients.

​

Our work is driven by a simple but transformative idea: neutrophils are not just blunt instruments of immunity - they are sophisticated, adaptable players whose potential as therapeutic targets is only beginning to be realized. By continuing to uncover the rules that govern neutrophil biology, we aim to redefine how inflammatory diseases, infectious diseases, cancer and tissue repair are treated in the future.